New York, February 23, 2017-- Moody's Investors Service assigned a Baa3 rating to Abbott Laboratories' proposed new senior unsecured note offering. The rating outlook is stable. There are no changes to Abbott's existing ratings including its Baa3 senior unsecured ratings and its Prime-3 commercial paper short-term rating.
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.